Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002

Current Medical Research and Opinion

Volumn 25, Issue 6, 2009, Pages 1535-1550

  Bottone Jr , Frank G ^a   Barry, William T ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Cyclooxygenase 2; Drug toxicity; Hemorrhage; Postmarketing; Product surveillance; Rofecoxib; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMLODIPINE BESYLATE; ANTICOAGULANT AGENT; ATENOLOL; ATORVASTATIN; CELECOXIB; CLOPIDOGREL; CONJUGATED ESTROGEN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DICLOFENAC POTASSIUM; DIGOXIN; ENALAPRIL; EXCEDRIN; FUROSEMIDE; HEPARIN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; KETOROLAC TROMETAMOL; LANSOPRAZOLE; LEVOTHYROXINE SODIUM; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; ORUVAIL UNK; PARACETAMOL; PIROXICAM; PREDNISONE; ROFECOXIB; SIMVASTATIN; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; VITAMIN; WARFARIN;

ADULT; AGE; AGED; ANGIONEUROTIC EDEMA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD VESSEL OCCLUSION; BRAIN HEMORRHAGE; CLINICAL TRIAL; COLON POLYP; COLORECTAL ADENOMA; CONGESTIVE HEART FAILURE; DEATH; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG FATALITY; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; EDEMA; EMBOLISM; EYELID EDEMA; FACE EDEMA; FAT EMBOLISM; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTRIC ULCER BLEEDING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENDER; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART MURMUR; HEART RATE; HUMAN; INCIDENCE; KIDNEY ARTERY EMBOLIZATION; LUNG EDEMA; LUNG EMBOLISM; MALE; MESENTERIC ARTERY EMBOLISM; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHARYNGEAL EDEMA; POSTMARKETING SURVEILLANCE; RECTUM HEMORRHAGE; RECTUM POLYP; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; STOMACH HEMORRHAGE; STOMACH ULCER; STROKE; SUDDEN DEATH; THROMBOSIS; TONGUE EDEMA; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VAGINA BLEEDING; VEIN EMBOLISM;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG INTERACTIONS; DRUG RECALLS; DRUG TOXICITY; FEMALE; HEMORRHAGE; HUMANS; LACTONES; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE; SULFONES; TIME FACTORS;

EID: 67649425383     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902953286     Document Type: Article

References (33)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-1205 (Pubitemid 28193431)
2. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999;281(9):824-829 (Pubitemid 29113743)
3. O'Connell KA, Wood JJ, Wise RP et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295(3):293-298 (Pubitemid 43112957)
4. Suh DC, Woodall BS, Shin SK et al. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000;34(12):1373-1379
5. Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol 2008;59(Suppl. 2):117-133
6. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343(21):1520-1528 (Pubitemid 30844348)
7. Merck and Company IWS, NJ, USA. Vioxx Product Insert, 2002.
8. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345(6):433-442 (Pubitemid 32747607)
9. Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104(19):2280-2288 (Pubitemid 33049509)
10. Mukherjee D, Nissen SE, Topol EJ. Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution. Cleve Clin J Med 2001;68(11):963-964 (Pubitemid 33100712)
11. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286(8):954-959 (Pubitemid 33010342)
12. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., 'Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,' N Engl J Med 2000;343:1520-8.
13. N Engl J Med 2005;353(26):2813-2814
14. FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001;19(6 Suppl. 25):S31-6. (Pubitemid 32998437)
15. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092-1102 (Pubitemid 40365350)
16. Merck withdraws Vioxx. FDA issues public health advisory. FDA Consum 2004;38(6):11.
17. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005;165(12):1363-1369
18. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308(6921): 81-106. (Pubitemid 24052591)
19. Kerr DJ, Dunn JA, Langman MJ et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007;357(4):360-369 (Pubitemid 47124136)
20. Mosholder AD, Pamer CA. Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants. J Child Adolesc Psychopharmacol 2006;16(1-2):33-36
21. Layton D, Heeley E, Shakir SA. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data. J Clin Pharm Ther 2004;29(2):171-181 (Pubitemid 38482483)
22. Schwartz JI, Bugianesi KJ, Ebel DL et al. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. Clin Pharmacol Ther 2000;68(6):626-636 (Pubitemid 32059989)
23. Weber J. Mathematical models in adverse drug reaction assessment. In: D'Arcy FF, Griffin JP (eds) Iatrogenic Diseases. Oxford: Oxford University Press, 1986:102-107
24. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167(13):1414-1419 (Pubitemid 47052441)
25. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167(16):1752-1759
26. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368(9549): 1771-1781 (Pubitemid 44739003)
27. Fosbol E, Gislason G, Jacobsen S et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2008;85(2):190-197
28. Gislason GH, Jacobsen S, Rasmussen JN et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase- 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113(25):2906-2913 (Pubitemid 44297231)
29. Kimmel SE, Berlin JA, Reilly M et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142(3):157-164 (Pubitemid 40189107)
30. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-1644 (Pubitemid 44511610)
31. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007;50(5):470-479 (Pubitemid 350146448)
32. Merck and Company IWS, NJ, USA. Celebrex® Product Insert, 2008.
33. Clark DW, Layton D, Shakir SA. Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology. Drug Saf 2004;27(7): 427-456